The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Fri., Mar. 29, 1:07 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #32. Intrexon Medistem

Acquirer: Intrexon (XON)
Acquiree: Medistem (MEDS)
Details: Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into a definitive agreement to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (OTCQB: MEDS) a pioneer in the development of Endometrial Regenerative Cells ("ERC" or "ERCs"), universal donor adult stem cells that stimulate new blood vessel formation and are capable of generating different tissues including heart, brain, pancreas, liver, bone, cartilage and lung. Intrexon intends to employ its integrated synthetic biology platforms to engineer a diverse array of cell-based therapeutic candidates using Medistem's multipotent ERCs.

Intrexon is engaged in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Using its suite of technologies, Co. designs, builds and regulates gene programs, which are DNA sequences that consist of primary genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. Co.'s primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary.

Open the XON Page at The Online Investor »

Intrexon is engaged in the field of synthetic biology, focusing on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. Using its suite of technologies, Co. designs, builds and regulates gene programs, which are DNA sequences that consist of primary genetic components. A single gene program or a complex, multi-genic program is fabricated and stored within a DNA vector. Vectors are segments of DNA used as a vehicle to transmit genetic information. Co.'s primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Hungary.

Open the MEDS Page at The Online Investor »

Company Name: 
Precigen Inc
Website: 
www.dna.com
Sector: 
Biotechnology
Company Name: 
TRxADE Health Inc
Stock buyback: 
MEDS buyback
Website: 
www.rx.trxade.com
Sector: 
Application Software
Number of ETFs Holding MEDS: 
1
Total Market Value Held by ETFs: 
$137790
Total Market Capitalization: 
$11.00M
% of Market Cap. Held by ETFs: 
1.25%
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Biotechnology M&A - Slide 32 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.